For BMS, Launching New Products Is The Start Of The Battle

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.    

BMS (Bristol) building
• Source: Shutterstock

Monica Shaw joined Bristol Myers Squibb Company as head of major markets in September. Based in Zurich, she is senior vice president and head of European markets, overseeing 22 countries – the company’s largest territories outside the US. But the industry is in a tricky place, contending with political pressure to cut drug prices and reduce spending more generally.

“It’s clear, particularly post-COVID, that a lot of payers have gone into cost containment mode. I think, for the first...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from C-Suite Speaks

Vigya test infogram

add a desc test

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

Crossject Tackles Needle Phobia In Emergency Settings

 

Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second

More from Leadership

In Vivo’s 2026 Rising Leaders

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.